Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SQZ Biotechnologies Company (SQZ : NYSE)
 
 • Company Description   
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.

Number of Employees: 116

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.26 Daily Weekly Monthly
20 Day Moving Average: 1,326,129 shares
Shares Outstanding: 28.15 (millions)
Market Capitalization: $91.76 (millions)
Beta: 3.73
52 Week High: $16.17
52 Week Low: $2.73
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.49% 16.57%
12 Week -34.01% -27.45%
Year To Date -63.49% -55.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 ARSENAL YARDS BLVD. SUITE 210
-
WATERTOWN,MA 02472
USA
ph: 617-758-8672
fax: -
investors@sqzbiotech.com http://www.sqzbiotech.com
 
 • General Corporate Information   
Officers
Armon Sharei - President; Chief Executive Officer and Director
Amy W. Schulman - Chairman and Director
Richard Capasso - Chief Accounting Officer
Paul Bolno - Director
Bernard Coulie - Director

Peer Information
SQZ Biotechnologies Company (CORR.)
SQZ Biotechnologies Company (RSPI)
SQZ Biotechnologies Company (CGXP)
SQZ Biotechnologies Company (BGEN)
SQZ Biotechnologies Company (GTBP)
SQZ Biotechnologies Company (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78472W104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 28.15
Most Recent Split Date: (:1)
Beta: 3.73
Market Capitalization: $91.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.81 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 41.43% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.87
Price/Cash Flow: -
Price / Sales: 3.74
EPS Growth
vs. Year Ago Period: -27.12%
vs. Previous Quarter: -82.93%
Sales Growth
vs. Year Ago Period: -47.40%
vs. Previous Quarter: -76.77%
ROE
03/31/22 - -57.79
12/31/21 - -47.47
09/30/21 - -51.18
ROA
03/31/22 - -32.71
12/31/21 - -28.30
09/30/21 - -30.52
Current Ratio
03/31/22 - 4.34
12/31/21 - 4.53
09/30/21 - 4.25
Quick Ratio
03/31/22 - 4.34
12/31/21 - 4.53
09/30/21 - 4.25
Operating Margin
03/31/22 - -303.43
12/31/21 - -253.68
09/30/21 - -432.38
Net Margin
03/31/22 - -303.43
12/31/21 - -253.68
09/30/21 - -432.38
Pre-Tax Margin
03/31/22 - -303.43
12/31/21 - -253.68
09/30/21 - -432.38
Book Value
03/31/22 - 3.73
12/31/21 - 4.42
09/30/21 - 4.75
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©